NLS Pharmaceutics AG (NLSP) Stock Analysis & Investment Frameworks
NLS Pharmaceutics AG (NLSP) stock analysis on Invetso. Review NLS Pharmaceutics AG’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
NLS Pharmaceutics AG Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: CH
NLS Pharmaceutics AG Key Financial Metrics
- Market Cap: $919601.00
- Revenue: $N/A
- ROE: 53.34%
- ROIC: -311.45%
- Dividend Yield: N/A
About NLS Pharmaceutics AG
NLS Pharmaceutics AG is a biopharmaceutical firm dedicated to researching and creating treatments for intricate and uncommon conditions affecting the central nervous system. Its primary focus includes advancing medications for narcolepsy, idiopathic hypersomnia, and various other unusual sleep conditions, alongside neurodevelopmental challenges like attention deficit hyperactivity disorder (ADHD). Key experimental compounds in its pipeline are Quilience, designed to address excessive daytime sleepiness and cataplexy, and Nolazol, which targets ADHD. Established in 2015, the company maintains its headquarters in Zurich, Switzerland.
NLS Pharmaceutics AG Investment Frameworks
Invetso analyzes NLS Pharmaceutics AG (NLSP) across the following frameworks:
- NLS Pharmaceutics AG 10Y Growth Potential
- NLS Pharmaceutics AG Scenario Analysis
- NLS Pharmaceutics AG Risks & Opportunities
- NLS Pharmaceutics AG Economic Moat
- NLS Pharmaceutics AG Business Model
- NLS Pharmaceutics AG Management
- NLS Pharmaceutics AG SWOT Analysis
- NLS Pharmaceutics AG Porter's 5 Forces
- NLS Pharmaceutics AG PESTLE Analysis
- NLS Pharmaceutics AG ESG Analysis